We scan new podcasts and send you the top 5 insights daily.
Regulators welcome validated CFD data because it replaces unnecessary wet experiments and wasted process media. While the manufacturing-focused ASME V&V 80 standard is still being drafted, drug developers can already submit manufacturing CFD models to the FDA by applying the existing ASME V&V 40 medical device standard's credibility assessment framework.
Instead of waiting for physical tech transfer runs, biotech startups can use CFD to determine whether a process refined in micro-bioreactors will run safely in a CDMO's specific reactor fleet. Performing this virtual scale-up in advance derisks facility selection, reduces timeline and financial commitments, and provides verifiable technical proof for prospective investors.
Christian Witz notes that biotech scientists frequently treat CFD as an intimidating tool requiring a dedicated physics or mathematics PhD. However, the real obstacle is that conventional CFD user interfaces have not been tailored to bioprocess workflows. Just as modern computer use does not require an IT technician, tailored interfaces allow routine process development scientists to employ CFD daily like Excel.
Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.
Early CFD adoption in biotech faltered because limited compute power forced engineers to use geometric simplifications, such as simulating a single periodic cake slice instead of the entire reactor cylinder. Bioreactors contain massive three-dimensional wrapping flows that cannot be captured in periodic wedge models. These simplifications produced inaccurate results, leading teams to experience poor outcomes and abandon simulation for years.
The acceptable ranges used in GMP manufacturing are typically defined by mathematical models built during process validation. Adopting a digital twin isn't introducing a foreign concept; it's simply deploying the same type of model in real-time with a human in the loop, rather than using a static, one-time calculation.
Many assume vast amounts of data are necessary for a digital twin. In reality, process validation data combined with a handful of manufacturing trends is often sufficient. The focus should be on data quality and its relevance to a specific business decision, not sheer quantity. This approach makes powerful modeling accessible much earlier.
The FDA's Advanced Manufacturing Technology designation, which Cellino received, challenges the belief that the agency is indifferent to manufacturing scale and cost. This program signals that regulators recognize manufacturing as a key bottleneck for patient access and are now collaborating with developers to accelerate scalable solutions.
The regulatory pathway for deploying models in manufacturing is not an unknown frontier. It involves a credibility assessment for the model itself, following standards like ASME VNP 40, and established GAMP procedures for validating the data interfaces. This treats the model and its integration as distinct, manageable components with clear guidelines.
Teams focus on clinical data for accelerated FDA designations but often underestimate the reality that this forces an equally accelerated timeline for Chemistry, Manufacturing, and Controls (CMC). Manufacturing scale-up, validation, and analytical testing must keep pace with the clinical program to avoid significant delays.
When deviations or disturbances occur in continuous bioprocessing, determining the exact volume of impacted material downstream is difficult. Through first-principle CFD and rapid response models across stirred tanks, connectors, filters, and chromatography units, teams can simulate the whole residence time distribution chain to pinpoint precisely which product must be discarded and which can be retained safely.